- ►publichealth.ru [PDF] D Daneman - The Lancet, 2006 - Elsevier Type 1 diabetes accounts for only about 5–10% of all cases of diabetes;
however, its incidence continues to increase worldwide and it has serious
short-term and long-term implications. The disorder has a strong genetic ... Cited by 126 - Related articles - All 27 versions
MJ Haller, MA Atkinson, D Schatz - The Pediatric Clinics of North America, 2005 - Elsevier Type 1 diabetes mellitus (T1D) is a heterogeneous disorder characterized by
autoimmune-mediated destruction of pancreatic beta cells that culminates in
absolute insulin deficiency. T1D is most commonly diagnosed in children and ... Cited by 35 - Related articles - All 17 versions
D Singh-Franco, G Robles, D Gazze - Clinical Therapeutics, 2007 - Elsevier Pramlintide is administered subcutaneously in the abdominal area or thigh
immediately before each main meal to achieve maximal reductions in post-prandial
glucose excursions. Its C max is reached within 20 minutes, and its t 1/2 ... Cited by 17 - Related articles - All 2 versions
- ►shouxi.net EA Eugster, G Francis… - Pediatrics, 2006 - Am Acad Pediatrics Insulin pump therapy has become increasingly popular for the treatment of type 1
diabetes in pediatric patients. Although significant experience has accrued with
the use of this modality in older children and adolescents, much less data ... Cited by 17 - Related articles - All 5 versions
M Rachmiel, K Perlman, D Daneman - The Pediatric Clinics of North America, 2005 - Elsevier Type 1 diabetes mellitus (T1D) is a chronic, metabolic disorder that most
commonly presents during childhood and is characterized by absolute insulin
deficiency. T1D is caused by selective immune-mediated autoreactive T-cell ... Cited by 15 - Related articles - All 3 versions
S Shalitin, M Phillip - Pediatric Diabetes, 2006 - interscience.wiley.com Abstract: Tight glycemic control of diabetic patients is associated with a
reduction in the risk of microvascular and macrovascular complications, yet with
elevated risk of severe episodes of hypoglycemia. The goal of "closing the ... Cited by 13 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org DG Marrero, J Crean, B Zhang, T Kellmeyer, … - Diabetes care, 2007 - Am Diabetes Assoc RESULTS—Pramlintide-treated patients reported greater treatment satisfaction
in most questionnaire responses. Treatment satisfaction was similar for
pramlintide-treated patients regardless of intensive insulin regimens (MDI ... Cited by 13 - Related articles - BL Direct - All 6 versions
LM RODRIGUEZ, KJ MASON, MW HAYMOND … - Pediatric Research, 2007 - journals.lww.com ABSTRACT: Pramlintide, a synthetic analog of amylin, improves postprandial
hyperglycemia. We compared subcutaneous (sc) pram- lintide injection with square
wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight ... Cited by 11 - Related articles - BL Direct - All 8 versions
WV Tamborlane - Pediatric Diabetes, 2006 - interscience.wiley.com Abstract: Although insulin pump or continuous subcutaneous insulin infusion
(CSII) treatment was first introduced more than 25 yr ago, very few children and
adolescents with type 1 diabetes mellitus (T1DM) utilized this therapy ... Cited by 11 - Related articles - BL Direct - All 3 versions
